- Home
- ANVS vs ACET Comparison
ANVS vs ACET Comparison
Compare ANVS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | ACET |
|---|---|---|
| Founded | 2008 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 93.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANVS | ACET |
|---|---|---|
| Price | $3.79 | $0.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $13.50 | $8.50 |
| AVG Volume (30 Days) | ★ 4.0M | 2.1M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.45 |
| 52 Week High | $6.37 | $1.11 |
Technical Indicators
Market Signals| Indicator | ANVS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 35.46 |
| Support Level | $4.12 | $0.50 |
| Resistance Level | $4.64 | $0.59 |
| Average True Range (ATR) | 0.53 | 0.05 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 18.03 | 11.53 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.